Market Access Changes To Deter Drugmaker Investment

Greece's government has unveiled further details of the country's pharmaceutical pricing and reimbursement reform, which BMI believes could have a severely detrimental effect on market access for pharmaceutical companies. In line with modifications in other European countries, BMI has introduced a new short-term core view for the industry: the use of price erosion mechanisms, including therapeutic reference pricing, will be increasingly introduced in Europe as a means of containing government health

To read the full article, please choose one of the following options: